Cellmid Growth Trifecta, page-16

Well it seems that the enthusiasm has been squashed out of the retail shareholders.. A most intriguing pair of announcements.

It would seem that the appointment of a new Lyramid CEO preempts an almost certain spin off. I wouldn't think that Bart would have accepted this opportunity if there wasn't a fair chance of success...as soon as the FDA provide Orphan Drug Designation. Has anyone checked the mailbox ? probably sitting on the bottom of the in-tray and may have the ceremonial "surprise" opening in the very near term.

So what leaves the CEO of Advandgen ? Where does that leave Maria ? Perhaps as new Chair ??

And where does the leave Kinera ? all a bit of a mystery really.

The push to expose value to the shareholders can have no more importance than to that of the CEO ? Is this an exit plan ?

regardless of the plan i think there are a few more ann to come before eofy.